MondegarAI
Velan Capital Investment Management LP

Q1 2025 · 13F-HR

Velan Capital Investment Management LPholdings as filed

Filed 2025-05-15 · accession 0000938552-25-000003

$97.2M
Reported value
47
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
427746102HRTXHERON THERAPEUTICS INC$15.4M15.8%6,986,744CommonSOLE
00445A100ACELYRIN INC$8.3M8.56%3,366,945CommonSOLE
85205L107SWTXUSDSPRINGWORKS THERAPEUTICS INC$8.2M8.42%185,520CommonSOLE
74365U107TARAPROTARA THERAPEUTICS INC$7.1M7.31%1,667,800CommonSOLE
74006W207PRAXPRAXIS PRECISION MEDICINES I$7.0M7.21%185,000CommonSOLE
89157D105TRMLTOURMALINE BIO INC$6.9M7.13%455,412CommonSOLE
471871202JSPRJASPER THERAPEUTICS INC$6.2M6.34%1,433,828CommonSOLE
925050106VRNAVERONA PHARMA PLC$6.0M6.20%95,000CommonSOLE
488445206ZVRAZEVRA THERAPEUTICS INC$5.0M5.12%665,000CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$4.4M4.55%300,000CommonSOLE
45779A846NSPRINSPIREMD INC$2.4M2.50%904,029CommonSOLE
810648105SCPHSCPHARMACEUTICALS INC$2.4M2.48%917,668CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$2.4M2.46%150,600CommonSOLE
76029N106REPLREPLIMUNE GROUP INC$1.8M1.83%182,083CommonSOLE
27966L306EDSAEDESA BIOTECH INC$1.7M1.73%687,500CommonSOLE
45783C200TILINSTIL BIO INC$1.2M1.23%69,000CommonSOLE
76200L309RZLTREZOLUTE INC$1.2M1.19%400,000CommonSOLE
28617K101ELDNELEDON PHARMACEUTICALS INC$1.1M1.13%323,973CommonSOLE
46489V302CATXPERSPECTIVE THERAPEUTICS INC$1.1M1.10%500,000CommonSOLE
374163103GERNGERON CORP$1.0M1.07%655,000CommonSOLE
45257U108IMNMIMMUNOME INC$1.0M1.06%153,500CommonSOLE
872381108TELATELA BIO INC$911,8400.94%747,410CommonSOLE
05338F306AVTXAVALO THERAPEUTICS INC$896,8960.92%111,972CommonSOLE
869367102SUTRO BIOPHARMA INC$670,1180.69%1,030,000CommonSOLE
91678A107UPBUPSTREAM BIO INC$654,8400.67%107,000CommonSOLE
88032L605TENXTENAX THERAPEUTICS INC$545,8310.56%83,333CommonSOLE
49721T507KPRXKIORA PHARMACEUTICALS INC$367,8910.38%122,223CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$313,2900.32%59,000CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$140,0000.14%80,000CommonSOLE
Y95308105WVEWAVE LIFE SCIENCES LTD$105,0400.11%13,000CommonSOLE
38341P102GOSSGOSSAMER BIO INC$82,5000.08%75,000CommonSOLE
29479A108ERASERASCA INC$68,5000.07%50,000CommonSOLE
014442107ALECALECTOR INC$67,6500.07%55,000CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$60,2000.06%28,000CommonSOLE
N71542109PRQRPROQR THRAPEUTICS N V$59,8500.06%45,000CommonSOLE
21077P108CNTXCONTEXT THERAPEUTICS INC$55,0800.06%90,000CommonSOLE
25056L103DSGNDESIGN THERAPEUTICS INC$54,0400.06%14,000CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$53,5500.06%35,000CommonSOLE
23284F105CTMXCYTOMX THERAPEUTICS INC$47,6850.05%75,000CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$46,9200.05%17,000CommonSOLE
92332V107VTYXUSDVENTYX BIOSCIENCES INC$46,0000.05%40,000CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS IN$38,7600.04%12,000CommonSOLE
69353Y103PMVPPMV PHARMACEUTICALS INC$38,1500.04%35,000CommonSOLE
690469101OVIDOVID THERAPEUTICS INC$30,2540.03%97,000CommonSOLE
50107A104KRON1USDKRONOS BIO INC$28,8750.03%35,000CommonSOLE
65343E108NXTCEURNEXTCURE INC$12,0080.01%25,000CommonSOLE
28623U101ELEVATION ONCOLOGY INC$11,6600.01%45,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.